Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
Hugel Inc. has forged a distribution partnership with Sihuan Pharmaceutical for its Letybo botulinum toxin product after becoming the first South Korean brand approved to enter the Chinese market.
China’s National Medical Products Administration recently approved Hugel's Letybo for local sales.
Sihuan Pharmaceutical, which has a network of over 10,000 hospitals and medical institutions, will expedite Hugel's entry into the Chinese botox market.
Hugel hopes to take a 30 percent share within three years of the product launch and is aspiring to become the top botox brand in the country.
The South Korean biopharmaceutical firm is also eyeing to enter the European market in 2021 and the US market in 2022.
The market is estimated to be worth 1.75 trillion won by 2025.
Hugel is now one of the four companies, including US’ Allergan, French company Ipsen’s Dysport, and Chinese company Lanzhou Institute of Biological Products’ Hengli, authorized to trade in the Chinese botox market.
Due to its continued economic growth and increasing attention for beauty and appearance, China is expected to have increased demand for BTX products.
